Nasal NK/T-cell lymphoma is a rare type of malignant lymphoma, accounting for approximately 2% to 10% of lymphomas. It is currently believed that the development of NK/T-cell lymphoma is associated with EBV infection, is highly aggressive, and has a rapid clinical progression with only a 6-12 month survival period if not treated immediately. Early lesions of nasal NK/T-cell lymphoma are sensitive to radiotherapy, and the integrated treatment modality of radiotherapy significantly improves its prognosis, with a current cure rate of more than 70%. Therefore, standardized radiotherapy should be received as soon as possible after diagnosis, and most patients can be cured. NK/T-cell lymphoma mostly originates in the nasal cavity and often invades the nasal turbinates, nasal septum and nasal skin. Clinical symptoms include nasal congestion, runny nose, bloody nose or epistaxis, sore throat, and discomfort in swallowing, which are easily misdiagnosed as “cold”, “rhinitis”, “deviated septum” or pharyngitis. Disruption of the midline is a prominent facial feature, such as nasal septum perforation, hard palate perforation, and facial skin involvement. Some patients have fever, night sweats and weight loss, which are clinically referred to as “B symptoms”. Because tumor cells often invade small blood vessels, resulting in ischemic necrosis of tumor tissues, some patients repeatedly biopsies are reported as “chronic inflammatory tissues”, which is easily misdiagnosed clinically and requires several times of sampling to confirm the diagnosis of this disease. A definite pathological diagnosis is the first step in the preparation for treatment. Systematic examination is also needed to clarify the clinical stage and the extent of disease invasion, and to formulate a corresponding treatment plan and determine the prognosis according to the early or late stage of the disease. Pre-treatment staging tests for nasal NK/T-cell lymphoma include: 1) MRI of nasal cavity and nasopharynx; 2) Enhanced CT of mediastinum, abdomen and pelvis; 3) Ultrasound of superficial lymph nodes throughout the body; 4) Routine blood, liver and kidney function and lactate dehydrogenase (LDH) test; 5) Hepatitis B virus and copy number test; 6) Peripheral blood EBV DNA copy number test; 7) Bone marrow aspiration, etc.; for patients with sufficient funds For patients with sufficient funds, whole-body PET-CT examination is highly recommended to more accurately define the scope of the disease and determine the clinical stage. The treatment of nasal NK/T-cell lymphoma requires a combination of radiotherapy and chemotherapy. Unlike the principle of chemotherapy-based treatment for most lymphomas, this lymphoma is poorly treated with chemotherapy alone, and radiation therapy is essential. The dose of radiation therapy for nasal NK/T-cell lymphoma is 50-60 Gy (25-30 sessions), and most patients can achieve complete remission and be cured. The new radiation therapy technique, intensity-modulated radiation therapy, can better protect normal tissues and reduce treatment complications. Our center is the first to carry out intensity-modulated radiation therapy technology in central China, and has accumulated rich clinical experience in nasal NK/T-cell lymphoma radiation therapy. Patients receiving radiation therapy alone often have good control of nasal marginal tumors, but the incidence of distant metastases is high, so reasonable chemotherapy is still necessary. A combination of radiotherapy and chemotherapy is currently advocated for early stage NK/T-cell lymphoma. The “CHOP” regimen is the classic regimen for chemotherapy of many lymphomas, but it is not sensitive for nasal NK/T-cell lymphoma and has been abandoned in our department. At present, the chemotherapy regimen of “pemantase + high-dose methotrexate + dexamethasone” is mostly used in our department, and this regimen has achieved good therapeutic effects in domestic and international studies, and studies in our department also show that its efficacy is significantly better than other regimens. For patients who cannot tolerate high-dose methotrexate or pemetrexate allergy, we have also achieved good results with GDP (gemcitabine + cisplatin + dexamethasone) regimen. Since our department carries out radiotherapy and chemotherapy at the same time, we can arrange the sequence of chemotherapy and radiotherapy more rationally, and make better use of the advantages of integrated radiotherapy and chemotherapy, and obtain a 70% cure rate. Therefore, once diagnosed with NK/T-cell lymphoma, one must build up confidence and receive standardized and reasonable radiotherapy as soon as possible.